FIELD: medicine.
SUBSTANCE: invention concerns a solid oral dosage form composition containing therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in amount exceeding 46 wt %. The oral dosage form represents a tablet or a film-coated tablet. Aliskiren tablet is made by wet granulation with using mixed organic solvents or organic binding solutions.
EFFECT: elimination of aqueous granulation provides high stability of the dosage form of aliskiren and prolonged shelf-life.
18 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2009 |
|
RU2438661C2 |
| ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
| GALENA COMPOSITION OF ALISKIREN AND HYDROCHLOROTHIAZIDE | 2007 |
|
RU2491058C2 |
| GALENIC FORMULATIONS OF ALISKIREN | 2008 |
|
RU2483718C2 |
| GALENICAL PREPARATIONS OF ORGANIC COMPOUNDS | 2010 |
|
RU2535090C2 |
| ADMINISTRATION OF RENIN INHIBITORS FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE | 2005 |
|
RU2407523C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
| ESCITALOPRAM AND HARD PHARMACETICAL COMPOSITION CONTAINING IT | 2007 |
|
RU2463039C2 |
| PHARMACEUTICAL COMPOSITION WITH ANTI-ISCHEMIC AND ANTIOXIDANT ACTIVITY AND METHOD FOR PREPARING IT | 2013 |
|
RU2545833C1 |
